Načítá se...
Clinical potential of treatment with semaglutide in type 2 diabetes patients
Glucagon-like receptor agonists (GLP-1RAs) are included in current national and international guidelines as second-line treatment especially in patients with type 2 diabetes and concomitant cardiovascular disease (CVD). First-generation GLP-1RAs were two- or once-daily injectables, but longer-acting...
Uloženo v:
| Vydáno v: | Drugs Context |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioExcel Publishing Ltd
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6905643/ https://ncbi.nlm.nih.gov/pubmed/31844422 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.212585 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|